CYCN Cyclerion Therapeutics Inc

Price (delayed)

$3.49

Market cap

$9.46M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.25

Enterprise value

$1.89M

Cyclerion Therapeutics is a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function. Cyclerion's lead program is CY6463, a novel, first-in-class, CNS-penetrant, sGC stimulator that modulates ...

Highlights
Cyclerion Therapeutics's EPS has soared by 89% YoY and by 57% from the previous quarter
The net income has surged by 88% year-on-year and by 51% since the previous quarter
The quick ratio has soared by 105% YoY but it has contracted by 7% from the previous quarter
The equity has contracted by 12% from the previous quarter but it has grown by 8% YoY
The company's gross profit has shrunk by 100% YoY
The revenue has dropped by 100% year-on-year

Key stats

What are the main financial stats of CYCN
Market
Shares outstanding
2.71M
Market cap
$9.46M
Enterprise value
$1.89M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.76
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$5.62M
EBITDA
-$5.62M
Free cash flow
-$21.25M
Per share
EPS
-$2.25
Free cash flow per share
-$9.09
Book value per share
$4.62
Revenue per share
$0
TBVPS
$5.72
Balance sheet
Total assets
$13.37M
Total liabilities
$2.09M
Debt
$0
Equity
$11.29M
Working capital
$5.94M
Liquidity
Debt to equity
0
Current ratio
3.85
Quick ratio
3.63
Net debt/EBITDA
1.35
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-42%
Return on equity
-63.3%
Return on invested capital
-600.1%
Return on capital employed
-49.8%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CYCN stock price

How has the Cyclerion Therapeutics stock price performed over time
Intraday
20.34%
1 week
13.31%
1 month
16.33%
1 year
-96.83%
YTD
4.18%
QTD
9.06%

Financial performance

How have Cyclerion Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$12.95M
Net income
-$5.26M
Gross margin
N/A
Net margin
N/A
The company's gross profit has shrunk by 100% YoY
The revenue has dropped by 100% year-on-year
The net income has surged by 88% year-on-year and by 51% since the previous quarter
The operating income has grown by 40% from the previous quarter and by 30% YoY

Growth

What is Cyclerion Therapeutics's growth rate over time

Valuation

What is Cyclerion Therapeutics stock price valuation
P/E
N/A
P/B
0.76
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Cyclerion Therapeutics's EPS has soared by 89% YoY and by 57% from the previous quarter
The stock's price to book (P/B) is 67% less than its last 4 quarters average of 2.0 and 65% less than its 5-year quarterly average of 1.9
The equity has contracted by 12% from the previous quarter but it has grown by 8% YoY
The revenue has dropped by 100% year-on-year

Efficiency

How efficient is Cyclerion Therapeutics business performance
CYCN's return on assets has surged by 70% year-on-year and by 47% since the previous quarter
The company's return on equity has surged by 68% YoY and by 52% QoQ

Dividends

What is CYCN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CYCN.

Financial health

How did Cyclerion Therapeutics financials performed over time
The quick ratio has soared by 105% YoY but it has contracted by 7% from the previous quarter
The current ratio has soared by 98% YoY but it has decreased by 9% from the previous quarter
Cyclerion Therapeutics's debt is 100% less than its equity
The equity has contracted by 12% from the previous quarter but it has grown by 8% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.